Chart-Typ:
Zeitraum:
| Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting | New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session Nello Mainolfi, Founder, President... ► Artikel lesen |
| Kymera Therapeutics, Inc.: Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting | KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294... ► Artikel lesen |
| Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |
| Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) | CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the... ► Artikel lesen |
| Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones | Patient Dosing and Enrollment Continue to Progress in Beacon Phase 1/2 Study of BEAM-101 in Severe Sickle Cell Disease; First Clinical Data Anticipated in Second Half of 2024 Phase 1 Trial Initiation... ► Artikel lesen |
| Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen |
| Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen |
| ROUNDUP/Aktien New York: Dow schwächer vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf zur Wochenmitte hat die Wall Street am Donnerstag daran angeknüpft. Dagegen verzeichnete die Technologiebörse Nasdaq eine freundliche Tendenz.... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
